| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Enlivex Ltd.$6.86
-0.54 (-7.3%)
D 32Pipeline Score Overvalued Biotech · Clinical
Market Cap
172.95 M
EPS
27.04
P/E Ratio
0.03 $
Value Trade
410.04 K
0.56 %
Week
-19.11 %
1 Month
-29.66 %
3 Month
-21.14 %
6 Month
-92.62 %
5 Year
-99.73 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
96.54 K
52 Week Range
0.66 - 2.10
% held by Insiders
85.43 %
% held by Institutions
1.51 %
Enterprise Value
167.73 M
Total Shares
241.77 M
Short %
4.7 %
Float Shares
32.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enlivex Ltd.
430Total events
3Upcoming
78Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 3
Event history 427
Jun 15, 2026
▲Patent GrantedAllocetraIP / Competition
Issuance of Australian patent covering Allocetra™ for osteoarthritis
osteoarthritissource ↗
Jun 15, 2026
▲First Patient DosedAllocetraTrial
First patient dosed at U.S. clinical site in Phase 2b trial of Allocetra™ for knee OA
moderate-to-severe age-related symptomatic primary knee osteoarthritissource ↗
Jun 15, 2026
▲Topline ReadoutAllocetraClinical Data
Positive three-month and six-month topline data from Phase 2b stage of ENX-CL-05-001
moderate-to-severe knee osteoarthritissource ↗
Jun 3, 2026
◆Oral PresentationAllocetraPresentation
Oral presentation of 3-month and 6-month data from Phase IIa trial at EULAR 2026
knee osteoarthritissource ↗
Jun 2, 2026
●Oral PresentationPresentation
Enlivex to present quality longevity model powered by prediction markets treasury at Proof of Talk 2026
Jun 1, 2026
▲First Patient DosedAllocetraTrial
First patient dosed in Phase IIb study in the United States
knee osteoarthritissource ↗
May 18, 2026
▲First Patient DosedAllocetraTrial
First patient dosed in US for Phase 2b trial of Allocetra in knee osteoarthritis
moderate-to-severe age-related symptomatic primary knee osteoarthritissource ↗
Apr 24, 2026
◆Poster PresentationAllocetraPresentation
Poster presentation of 3-month and 6-month Phase IIa data for Allocetra at OARSI 2026
moderate-to-severe knee osteoarthritissource ↗
Apr 21, 2026
▲Other Regulator MilestoneAllocetraEx-US Regulatory
CTA approval by Danish Medicines Agency for Phase 2b trial of Allocetra
age-related primary moderate-to-severe knee osteoarthritissource ↗
Apr 21, 2026
▲IND ClearanceAllocetraIND
FDA clearance for Phase 2b trial of Allocetra
age-related primary moderate-to-severe knee osteoarthritissource ↗
Drug Pipeline Intelligence
D32
Pipeline Score $36M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 40%
Micro Cap (rank 548 of 911)
Percentile RankEnlivex Ltd. faces pipeline headwinds (32/100), with $395M risk-adjusted pipeline value, led by Allocetra in Primary Knee Osteoarthritis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allocetra Small molecule | Primary Knee Osteoarthritis | Phase 2 | NCT07580716 | 17% | $216M | RECRUITING | 270 | VERY_FAST | B (64) | Apr 1, 2028 | - | LOW Jun 18, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Allocetra | knee osteoarthritis | Phase 2a | 2026-06-01 | statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function in idiopathic age-related osteoarthritis patients (≥60 years) Read More | Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 Read More | |
Allocetra | knee osteoarthritis | Phase 2a | 2026-06-01 | statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function in idiopathic age-related osteoarthritis patients (≥60 years) Read More | Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 Read More | |
Allocetra | knee osteoarthritis | Phase 2a | 2026-06-01 | statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function in idiopathic age-related osteoarthritis patients (≥60 years) Read More | Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENLV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ENLV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ENLVEnlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Enlivex Ltd. announced a 1-for-15 reverse stock split effective July 9, 2026. This action will reduce the number of authorized shares and increase the par value per share. The reverse split aims to enhance the company's market presence and trading dynamics without affecting shareholders' ownership percentages. The company's shares will continue to trade under the symbol 'ENLV' on the Nasdaq Capital Market.
Read more →ENLVEnlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
Enlivex Ltd. announced the listing of its primary treasury asset, the RAIN token, on the Gate cryptocurrency exchange, effective June 24, 2026. This listing is expected to enhance the token's market access and liquidity, as Gate is ranked second globally in spot trading volume. Enlivex's treasury strategy focuses on acquiring RAIN tokens, which currently hold a significant total value.
Read more →ENLVEnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Enlivex Ltd. has reported holding 79,568,550,005 RAIN tokens valued at around $1.14 billion as of June 20, 2026. The company’s treasury metrics show a NAV per share of $4.67, reflecting its digital asset strategy. Enlivex is also advancing its Allocetra™ immunotherapy targeting inflammatory conditions associated with aging.
Read more →ENLVEnlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Enlivex Ltd. announced the issuance of an Australian patent for Allocetra™, aimed at treating osteoarthritis. This patent enhances their intellectual property protection until at least 2040. The company has also initiated a Phase 2b clinical trial for Allocetra™ in patients with moderate-to-severe knee osteoarthritis, following positive results from earlier trials.
Read more →ENLVENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
Enlivex Ltd. announced its participation as a Gold Sponsor at Proof of Talk 2026 in Paris, where CEO Dr. Oren Hershkovitz will present the company's unique model combining quality longevity therapeutics with a prediction markets treasury. The event will gather approximately 2,500 decision-makers from various sectors, highlighting the growing institutional interest in prediction markets. Enlivex aims to showcase its integrated approach to capital allocation and clinical development.
Read more →ENLV▲ +6.6%on this newsshared move
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
Enlivex Ltd. announced that Allocetra showed durable efficacy in a Phase IIa trial for knee osteoarthritis, with results selected for an oral presentation at the EULAR 2026 congress. The trial demonstrated a statistically significant reduction in pain and improved function in patients aged 60 and above. The findings support the progression of Allocetra into a Phase IIb study.
Read more →ENLVEnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
Enlivex Ltd. announced a significant update regarding its RAIN token holdings, valued at approximately $1.16 billion. The Rain Foundation has appointed five industry leaders to its advisory board to support the growth of the Rain protocol. The protocol has gained traction with over 29,000 users and a $100 million liquidity commitment, making it the third-largest prediction market globally.
Read more →ENLV▲ +14.3%on this news· ran to +26% by day 3shared move
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
Enlivex Ltd. announced that its Rain protocol has secured a $100 million liquidity commitment, positioning it as the third-largest prediction market globally. This strategic move is expected to enhance market depth and infrastructure ahead of the FIFA World Cup. Enlivex holds a significant amount of RAIN tokens, reinforcing its treasury strategy.
Read more →ENLVEnlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Ltd. has announced the dosing of the first patient in the U.S. as part of its Phase 2b trial for Allocetra, targeting moderate-to-severe knee osteoarthritis. This trial follows FDA IND clearance and DKMA approval, aiming to evaluate the treatment's efficacy and safety. The trial involves multiple centers across the U.S., Denmark, and Poland, focusing on pain relief and quality of life improvements.
Read more →ENLVEnlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Enlivex Ltd. has received a notification from Nasdaq regarding its ordinary shares' bid price falling below the required $1.00 threshold. The company has a 180-day period to regain compliance by maintaining the minimum bid price for at least 10 consecutive business days. If compliance is not achieved, Enlivex may qualify for an additional compliance period or face potential delisting.
Read more →ENLVEnlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
Enlivex Ltd. announced that its primary digital treasury asset, the RAIN token, has been officially listed on the HTX cryptocurrency exchange as of April 29, 2026. This development significantly improves the token's accessibility and liquidity, leveraging HTX's extensive user base and trading volume. Additionally, the company reported an increase in total RAIN holdings to approximately 78.8 billion tokens, valued at $567 million. Enlivex's strategy combines the use of RAIN for decentralized predictions while advancing clinical programs related to longevity, particularly targeting age-related conditions.
Read more →ENLV▼ -6.4%on this newsshared move
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
Enlivex Ltd. announced an increase in its total RAIN token holdings to 78,819,756,062 tokens, valued at $567 million as of April 27, 2026. The acquisitions were completed at a substantial discount to the market price, reflecting the company's disciplined treasury strategy. CEO Oren Hershkovitz noted that this strategy aligns with a rising institutional interest in prediction markets. Enlivex is committed to leveraging its digital asset treasury alongside its clinical programs focused on longevity therapeutics.
Read more →ENLVEnlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Enlivex Ltd. announced it will present clinical data from its Phase IIa trial of Allocetra™ at the OARSI 2026 World Congress. The data shows significant improvements in pain and function for patients with moderate-to-severe knee osteoarthritis. The presentations will be led by Prof. Philip Conaghan, highlighting the novel immunomodulating mechanism of Allocetra™.
Read more →ENLVEnlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark
Enlivex Ltd. has announced that it has secured regulatory approval from the Danish Medicines Agency for its Phase 2b clinical trial of Allocetra, aimed at treating moderate-to-severe knee osteoarthritis. This follows a similar approval from the FDA, marking a significant step in the company's global strategy. The trial will involve patient enrollment across multiple countries, including Denmark, the United States, and Poland. Allocetra's unique immunomodulatory mechanism aims to address inflammation associated with aging, potentially improving the quality of life for patients suffering from this common condition.
Read more →ENLV▲ +12%on this news
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
Enlivex Ltd. has announced the launch of ENLVon, a tokenized representation of its ordinary shares on Ondo's Global Markets platform. This initiative allows non-U.S. investors to access Enlivex's shares without traditional brokerage accounts. The tokenization aims to broaden investor access and integrate with various financial applications, while also highlighting potential risks in digital asset markets.
Read more →ENLV▼ -9.2%on this news· ran to -22% by day 3
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
Enlivex Ltd. announced that the Rain Foundation has launched an AI agent interface, OpenClaw, allowing users to create live prediction markets with a single prompt. The Rain Foundation also introduced a $5 million grant program to support developers in building independent prediction markets. This initiative aims to enhance the accessibility and growth of decentralized prediction markets.
Read more →ENLV▲ +9.1%on this newsshared move
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Enlivex Ltd. reported impressive financial results for the year ended December 31, 2025, with a net income of $1.23 billion and diluted earnings per share of $25.48. The company's success is attributed to the appreciation of its treasury and treasury-related assets. Enlivex continues to advance its clinical-stage immunotherapy, Allocetra™, while also leveraging a prediction markets treasury strategy. This dual approach positions the company favorably in the longevity therapeutics market.
Read more →ENLVEnlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
Enlivex Ltd. has secured $21 million in debt financing, convertible into ordinary shares at a premium. The company also exercised an option to acquire additional RAIN tokens at a discounted price and extended the acquisition option's duration. Furthermore, a $20 million share repurchase program was approved to enhance shareholder value.
Read more →ENLV▲ +8.8%on this newsshared move
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis Enlivex's first regulatory ap
Enlivex Ltd. has received FDA clearance to begin a Phase 2b clinical trial for its immunotherapy Allocetra, aimed at treating moderate-to-severe knee osteoarthritis in elderly patients. This trial will assess the efficacy and safety of Allocetra through intra-articular injections. The company highlights that knee osteoarthritis significantly affects the aging population and believes Allocetra could meet significant medical needs. This marks Enlivex's first regulatory approval under its dual-engine value creation model, indicating progress in its clinical-stage longevity program.
Read more →ENLV▼ -5.6%on this newsshared move
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program $21 Million debt financing, convertible to ENLV ordinary shares at fixed
Enlivex Ltd. has announced a $21 million debt financing agreement with The Lind Partners, providing it with approximately $18.7 million in net proceeds. The company plans to use the funds to execute its operating strategy and has also exercised an option to acquire additional RAIN tokens at a favorable price. Furthermore, Enlivex's Board approved a $20 million share repurchase program aimed at potentially increasing shareholder value. This series of moves is part of the company's ongoing strategy in capital allocation and investment in prediction markets.
Read more →ENLVCERTIFICATE OF CHANGE OF NAME This is to certify that the company: Company Number: 514716489 Changed its name in Israel according to Companies Laws in the State of Israel, and beginning of 10TH FEBRUARY 2026 it will be c
Enlivex Therapeutics Ltd, with Company Number 514716489, has officially changed its name to Enlivex Ltd in accordance with the Companies Laws of Israel. This name change will be effective starting February 10, 2026. The notification was certified by Shuli Avni-Shoham, the registrar of companies at the Israeli Corporations Authority. Such changes often reflect strategic decisions aiming for better alignment in corporate branding.
Read more →ENLVEnlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Enlivex Therapeutics has successfully listed its RAIN token on Kraken, the second-largest U.S. cryptocurrency exchange. This listing is anticipated to improve liquidity and accessibility for the token, which serves as a governance and utility asset in a decentralized protocol. Enlivex aims to leverage this listing to enhance its treasury strategy and provide investors with exposure to digital assets.
Read more →ENLVArticles of Association of Enlivex Therapeutics Ltd. A Company Limited by Shares Under The Companies Law, 5759-1999 Chapter 1 General 1 Chapter 2 Shares and Share Capital 2 Chapter 3 General Meetings 5 Chapter 4 The Boar
The Articles of Association for Enlivex Therapeutics Ltd. outline the company's structure, including provisions for the Board of Directors, share capital, and shareholder rights. Key chapters detail governance procedures, including the authority of the General Meeting and terms of directorship. The company aims to engage in any lawful business while ensuring limited liability for its shareholders. Additionally, provisions for indemnification and insurance of office holders are included, ensuring protection against certain liabilities.
Read more →ENLV▲ +8.3%on this news
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Enlivex Therapeutics has announced the listing of its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, effective January 21, 2026. This listing is anticipated to improve market access and liquidity for RAIN, which serves as a governance and utility token within a decentralized protocol. Enlivex aims to leverage this strategy to enhance its digital asset treasury and provide investor exposure to RAIN.
Read more →ENLVEnlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Enlivex Therapeutics has announced its voluntary delisting from the Tel Aviv Stock Exchange to focus exclusively on trading on Nasdaq. This decision is expected to reduce administrative costs and enhance liquidity. The last trading day on TASE is anticipated to be April 23, 2026, with delisting occurring shortly after. The company will continue to operate under U.S. regulations and maintain its clinical focus on osteoarthritis treatments.
Read more →ENLVEnlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange The listing on one of the world's largest global cryptocurrency exchanges expands market access and secondary liqu
Enlivex Therapeutics has listed its RAIN token on KuCoin, a leading cryptocurrency exchange, effective January 6, 2026. This listing aims to enhance market access and improve liquidity for the company's primary treasury asset. The RAIN token plays a significant role in Enlivex’s digital asset treasury strategy, which is centered around utilizing cryptocurrencies to support its financial positioning. The company also continues its focus on the clinical development of Allocetra, aimed at treating osteoarthritis.
Read more →ENLVENLIVEX THERAPEUTICS LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on
Enlivex Therapeutics Ltd. has announced an Extraordinary General Meeting of Shareholders to take place on February 3, 2026. The meeting will address several proposals, including amendments to the Articles of Association and the approval of a reverse share split. Shareholders of record as of December 24, 2025, are entitled to vote, and specific voting instructions have been provided. The recommended changes by the board reflect the company's strategic intentions moving forward.
Read more →ENLV▲ +6.4%on this news
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development Nes-Ziona, Israel
Enlivex Therapeutics Ltd. will conduct a virtual fireside chat on December 11, 2025, featuring Executive Chairman Shai Novik. The discussion will outline the company's recently secured $212 million private placement and its innovative strategy for RAIN token accumulation. Additionally, Novik will provide updates on the ongoing clinical development of Allocetra, a treatment for osteoarthritis, which affects millions globally. This strategic focus comes amidst numerous challenges within the drug development landscape.
Read more →ENLVEnlivex Announces Closing of Previously Announced $212,000,000 Private Placement - Enlivex has adopted the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN
Enlivex Therapeutics has successfully closed a $212 million private placement to fund its innovative treasury strategy involving RAIN prediction markets tokens. This marks Enlivex as the first publicly traded company to adopt such a strategy, aiming to provide greater transparency and community engagement in its market operations. The company is concurrently advancing clinical trials for AllocetraTM, a promising treatment for knee osteoarthritis, a condition affecting millions globally. With the appointment of former Italian Prime Minister Matteo Renzi to its Board, Enlivex strengthens its leadership and vision for future developments.
Read more →ENLV▲ +13.7%on this newsshared move
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
Enlivex Therapeutics announced positive six-month data from its Phase IIa trial of Allocetra™ for knee osteoarthritis. The results reaffirm earlier findings and highlight the treatment's potential to provide sustained pain relief and improved function in patients. The company plans to initiate a Phase IIb trial in 2026 to further evaluate Allocetra™'s efficacy.
Read more →ENLV▲ +13.7%on this newsshared move
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
Enlivex Therapeutics has announced a private placement of $212 million to implement a pioneering treasury strategy centered on the RAIN prediction markets token. The appointment of former Italian Prime Minister Matteo Renzi to the Board is expected to enhance the company's governance. Enlivex will continue to develop Allocetra™, a potential treatment for knee osteoarthritis, addressing a significant medical need. The transaction is scheduled to close by November 25, 2025, pending customary conditions.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CO
Enlivex Therapeutics Ltd. has released its condensed consolidated financial statements for the periods ending September 30, 2025, and December 31, 2024. The company reported a net loss of $2,205, showing a reduction compared to the previous year's loss of $2,602 in Q3. Total assets decreased significantly from $27,687 in 2024 to $20,938 in 2025, indicating challenges in maintaining financial stability. Additionally, total shareholders' equity has fallen from $23,589 to $17,481 during the same period, reflecting ongoing financial strain.
Read more →ENLVEnlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Enlivex Therapeutics announced it will present Phase IIa data for Allocetra at ACR Convergence 2025. The study shows significant improvement in pain and function for patients with moderate-to-severe knee osteoarthritis. The presentation will be led by Prof. Philip Conaghan, a renowned expert in the field. This data is crucial for understanding Allocetra's potential benefits.
Read more →ENLVD. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Enlivex Therapeutics will participate in a KOL webinar hosted by D. Boral Capital on September 30, 2025. The webinar will discuss the promising Phase IIa data from Enlivex's Allocetra™ program for knee osteoarthritis, highlighting significant pain reduction and functional improvements. Leading experts in musculoskeletal disease will share insights on the potential impact of these findings.
Read more →ENLVENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on November 10, 2025 Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders (the ȁ
Enlivex Therapeutics Ltd. is scheduled to hold its Annual General Meeting of Shareholders on November 10, 2025, at 7:00 p.m. Israel time. Key agenda items include the election of board members, an increase in authorized share capital, and the re-appointment of the company's independent auditors. Shareholders of record as of October 3, 2025, are entitled to vote, and various voting methods are provided to ensure participation. Additional details regarding the proposals will be made available through the company's proxy statement.
Read more →ENLV▲ +5.4%on this news
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Enlivex Therapeutics has announced positive topline results from its Phase IIa trial of Allocetra™ for knee osteoarthritis, indicating significant improvements in pain and function. The CEO highlighted the potential of Allocetra™ as a leading treatment option for patients with age-related osteoarthritis. The company plans to advance Allocetra™ towards late-stage development and is exploring partnership opportunities.
Read more →ENLVEnlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Enlivex Therapeutics has announced the issuance of an Israeli patent for Allocetra, aimed at treating osteoarthritis. The patent extends intellectual property protection until at least 2040. Recent Phase IIa trial results showed significant improvements in knee pain and function among patients treated with Allocetra compared to placebo. The company aims to expand its patent portfolio in major jurisdictions.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
Enlivex Therapeutics Ltd. has released its condensed consolidated financial statements for the six-month period ending June 30, 2025. The company reported a net loss of $5,320, down from $7,236 in the same period of 2024, indicating some improvement. However, total shareholders' equity declined to $19,054, reflecting ongoing financial challenges. The company's cash and cash equivalents also saw a significant decrease, raising concerns about its liquidity and sustainability. Research and development expenses continue to be a major cost driver as the company pursues its clinical stage immunotherapy developments.
Read more →ENLV▼ -31.3%on this news· ran to -43% by day 3
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
Enlivex Therapeutics announced positive topline data from its Phase IIa trial of Allocetra in patients with moderate-to-severe knee osteoarthritis. The trial showed significant improvements in knee pain and function, particularly in older patients. The treatment was well-tolerated with no severe adverse events reported. A webinar will provide further insights into the results.
Read more →ENLV▼ -31.3%on this news· ran to -43% by day 3shared move
ENLIVEX THERAPEUTICS PHASE IIA TOPLINE RESULTS Aug 2025 These slides and the accompanying oral presentation contain forward - looking statements and information. Forward - looking statements are subject to known and unkn
Enlivex Therapeutics announced the topline results of its Phase IIa study for Allocetra, a cell therapy aimed at treating inflammatory diseases. The study reported a favorable safety profile and positive treatment effect, indicating potential for significant advancements in treatment options. Additionally, a specific responder profile was identified, which could represent more than 50% of the knee osteoarthritis market. However, the company acknowledged that forward-looking statements come with inherent risks and uncertainties.
Read more →ENLV▲ +14.1%on this news· ran to -33% by day 3shared move
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Enlivex Therapeutics will host a webinar on August 18, 2025, to present topline results from its Phase IIa trial of Allocetra™ for moderate to severe knee osteoarthritis. The study is a double-blind, randomized, placebo-controlled trial assessing safety and efficacy. An interim analysis suggests expanding patient enrollment, with 134 patients completing the 3-month follow-up, marking key progress in the trial.
Read more →ENLV▲ +12.3%on this news· ran to +33% by day 3
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Enlivex Therapeutics has confirmed that all patients in its Phase II trial of Allocetra™ for knee osteoarthritis have completed the required follow-up period. The company is set to announce topline data on August 18, 2025, which will include key efficacy endpoints related to safety and joint function. The trial aims to provide insights into the treatment's effectiveness in a significant patient population.
Read more →ENLV▲ +12.3%on this news· ran to +33% by day 3shared move
Enlivex Reaffirms
Enlivex Therapeutics has announced that all 134 patients in its Phase II clinical trial of Allocetra for knee osteoarthritis have completed a three-month follow-up. The data is currently undergoing analysis, with results expected to be publicly released on August 18, 2025. The trial consists of two stages, focusing on safety and efficacy, and aims to establish a strong signal in a responder population for future development. The trial's endpoints involve measuring joint pain and function in comparison to placebo at various intervals.
Read more →ENLVEnlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Enlivex Therapeutics will present clinical data on Allocetra at the EULAR Congress in Barcelona, focusing on its effects in knee osteoarthritis. The therapy has shown favorable safety and efficacy in Phase I/II trials, with significant pain reduction and improved joint function. The company expects to release topline data from the Phase II trial by August 2025.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDA
Enlivex Therapeutics Ltd. released its condensed consolidated financial statements for the first quarter of 2025, reporting a net loss of $3.45 million. The company generated no revenues during the period and has accumulated significant losses, totaling over $130 million since its inception. Current assets decreased from $25.99 million to $22.65 million, while total liabilities and equity are also down. The ongoing lack of revenues and increasing deficit raises concerns about the company's financial stability and future development plans.
Read more →ENLVEnlivex Selected to Present at Israeli BioMed 2025 Conference
Enlivex Therapeutics has been chosen to present at the Israeli BioMed 2025 Conference, focusing on their macrophage reprogramming therapy, Allocetra™. The presentation will discuss its potential in treating inflammatory diseases. Recent trials show promising results in pain reduction and joint function improvement for osteoarthritis. Further data is anticipated in 2025.
Read more →ENLVEnlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
Enlivex Therapeutics will present two poster abstracts on Allocetra™ at the OARSI 2025 World Congress. The presentations will focus on Allocetra™'s mechanism in addressing immune imbalance in osteoarthritis. Data from preclinical and clinical studies suggest it may offer significant pain reduction and improved joint function, potentially benefiting millions of patients.
Read more →ENLVEnlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics has completed patient enrollment for the Phase II stage of its Phase I/II trial evaluating the efficacy of Allocetra in patients with moderate to severe knee osteoarthritis. A total of 133 patients were randomized and treated, following positive interim results from the Phase I stage, which indicated significant improvements in key efficacy endpoints. The company anticipates releasing topline data by August 2025, with a focus on evaluating joint pain and function against a placebo. This trial represents a notable step towards exploring new treatment options for a condition affecting millions worldwide.
Read more →ENLV▼ -6.3%on this news
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive d
Enlivex Therapeutics has announced the dosing of the first patient in a Phase I trial evaluating Allocetra for the treatment of TMJ osteoarthritis. The trial aims to assess the safety, tolerability, and initial efficacy of Allocetra, which is designed to reprogram macrophages. Conducted at Sheba Medical Center, the study will enroll six patients who have not responded adequately to standard treatments. Initial results show the procedure was completed successfully without any complications.
Read more →ENLVENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consoli
Enlivex Therapeutics Ltd. has released its financial statements as of December 31, 2024, which include a thorough audit of its financial position and internal controls. The independent auditors confirmed that the financial statements conform to U.S. generally accepted accounting principles, presenting a fair view of the company's operations and cash flows. The audit included an assessment of the company's internal control over financial reporting. The firm has been the auditor for Enlivex since 2013, indicating a long-standing relationship and continuity in oversight.
Read more →ENLV▼ -5.7%on this news
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics has received a notice of allowance for a patent application from the China National Intellectual Property Administration for the use of Allocetra in treating osteoarthritis patients. This patent, once issued, will offer protection in China until at least 2040. Additionally, positive interim results from a Phase I/II trial of Allocetra have been reported, indicating its potential efficacy in moderate to severe knee osteoarthritis. The company anticipates this patent to be formally granted in the first half of 2025, bolstering its intellectual property portfolio significantly.
Read more →ENLV▲ +5.9%on this news· ran to +17% by day 3
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra Trial in Knee Osteoarthritis Ness-Ziona, Israel
Enlivex Therapeutics has announced a webinar to present positive interim data from their Phase I/II Allocetra trial focused on knee osteoarthritis. The trial reported a significant average pain reduction of 47% and a 46% improvement in joint function six months post-treatment. Remarkably, 83% of patients remained responders, and no serious adverse events were recorded. The CEO expressed optimism about Allocetra's potential as a breakthrough treatment, emphasizing its safety and efficacy.
Read more →ENLV▼ -15%on this newsshared move
Enlivex Announces Positive Interim Data - Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics Ltd. announced positive interim data from its Phase I trial for Allocetra, revealing a statistically significant average pain reduction of 47.0% in patients with moderate to severe knee osteoarthritis after six months. The data aligns with prior three-month results, suggesting a durable response to the treatment. The company is continuing its patient recruitment for the Phase II stage, expecting topline data readout by the third quarter of 2025. These results are significant in the context of knee osteoarthritis, a condition affecting millions worldwide.
Read more →ENLVEnlivex Issues Urgent Statement on Fraudulent News Dissemination Ness-Ziona, Israel
Enlivex Therapeutics Ltd. issued an urgent statement addressing a misleading report by Tipranks.com, which falsely claimed that the company suspended stock trading due to an internal investigation. The company strongly refuted these allegations, clarifying that operations are normal and share trading continues unimpeded. Enlivex's CEO emphasized the severity of the misinformation and the intention to take legal action against its sources. The company continues to focus on its clinical-stage immunotherapy programs, including Allocetra, aimed at osteoarthritis treatment.
Read more →ENLVEnlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Ness-Ziona, Israel
Enlivex Therapeutics Ltd. has received regulatory authorization from the Israeli Ministry of Health to initiate a Phase I trial for Allocetra, aimed at treating patients with TMJ osteoarthritis. The trial seeks to assess the safety, tolerability, and initial efficacy of Allocetra in patients who have not responded to conventional treatments. Conducted in partnership with Sheba Medical Center, this study will involve six patients and will focus on both safety and efficacy endpoints over a period of up to 12 months. The successful development of Allocetra may provide new therapeutic options for this condition, addressing an important unmet medical need.
Read more →ENLV▲ +20.4%on this news
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics has announced positive interim efficacy data from its Allocetra trial involving patients with moderate to severe knee osteoarthritis. The Phase I stage was completed successfully, showing significant improvements in joint pain and functionality after treatment. The data indicates a statistically significant reduction in pain and improvement in knee function. The trial is progressing to a Phase II stage to further evaluate the efficacy and safety of Allocetra.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CO
Enlivex Therapeutics Ltd. has reported its condensed consolidated financial statements for the third quarter and nine-month period ending September 30, 2024. The company experienced an increase in cash and cash equivalents, rising to $2,772, while total assets decreased from $36,831 in December 2023 to $29,797 by September 2024. Despite maintaining a considerable shareholder equity of $26,587, the company reported a notable net loss of $2,602 for Q3 2024, reflecting ongoing operational challenges and an accumulated deficit totaling $121,931.
Read more →ENLV▼ -5.2%on this news· ran to -18% by day 1
Enlivex Adopts Bitcoin Treasury Reserve Strategy
Enlivex Therapeutics Ltd. has announced a strategic move to adopt Bitcoin as part of its treasury reserve, with an investment of up to $1 million. The company's CEO, Oren Hershkovitz, believes that Bitcoin's increasing acceptance and potential as a hedge against inflation can benefit their cash management strategy. While this decision reflects a modern take on asset management, it carries risks linked to cryptocurrency market volatility and the uncertainties of clinical product revenues.
Read more →ENLV▼ -5.2%on this news· ran to -18% by day 1
Enlivex Adopts Bitcoin Treasury Reserve Strategy Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has adopted a Bitcoin treasury reserve strategy, approving the purchase of up to $1 million in Bitcoin as part of its cash management efforts. The CEO, Oren Hershkovitz, noted the growing demand for Bitcoin and its acceptance as a medium of exchange. By incorporating Bitcoin, Enlivex aims to enhance its financial position, potentially using it as a hedge against inflation. However, the company's forward-looking statements highlight various risks related to product development and market conditions.
Read more →ENLV▼ -8.5%on this news
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has reported the successful dosing of the first patient in a Phase I clinical trial examining Allocetra for psoriatic arthritis. This study aims to evaluate the treatment's safety, tolerability, and potential therapeutic effects in patients unresponsive to conventional therapies. The trial will eventually enroll six patients, and preliminary assessments showed no safety issues following the first dosage. As Enlivex explores the application of Allocetra, it highlights the significant market need for effective treatments in higher-grade inflammatory conditions.
Read more →ENLVEnlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics has announced the enrollment and dosing of the first 10 patients in the Phase II stage of its Allocetra trial for moderate to severe knee osteoarthritis. This milestone follows a recommendation from the independent Data and Safety Monitoring Board to proceed with this phase, after successful completion of the Phase I safety run-in. The trial aims to evaluate joint pain and function over a period of 12 months using a double-blind and placebo-controlled approach. No safety concerns were identified during the initial dosing of participants.
Read more →ENLVEnlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics announced the receipt of a notice of allowance from the Japanese Patent Office for its patent application regarding Allocetra for osteoarthritis treatment. This patent will secure intellectual property protection until at least 2040, reflecting the company's commitment to safeguarding its innovations. The CEO emphasized that this development highlights the successful execution of Enlivex's global IP strategy as they aim to establish Allocetra as a breakthrough therapy in a field lacking effective treatment alternatives.
Read more →ENLV▲ +6.9%on this news
Enlivex Therapeutics Ltd. (the " Company ") Amended and Restated Compensation Policy for Company Office Holders 1. The Objective of the Document The objective of this compensation policy (the " Policy ") is to define and
Enlivex Therapeutics Ltd. has announced an Amended and Restated Compensation Policy for its Office Holders, in accordance with the Israeli Companies Law. The policy outlines the guidelines and frameworks to ensure that the remuneration is competitive and aligned with global practices. Approval of the compensation terms will still be subject to the Company's authorized bodies and applicable laws, with the intention to attract talented professionals. This new policy is positioned to enhance employee relations and sustain the company's operational goals over the next three years.
Read more →ENLV▲ +8.2%on this news
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics has received authorization from the Danish Medicines Agency to initiate the Phase II stage of its clinical trial for Allocetra, targeting moderate to severe knee osteoarthritis. This decision follows a recommendation from the Data and Safety Monitoring Board based on safety data from Phase I. The Phase II trial will evaluate the efficacy of Allocetra through a randomized, placebo-controlled study, focusing on joint pain and function over a 12-month period. This step reflects an important milestone for Enlivex in addressing the significant burden of knee osteoarthritis globally.
Read more →ENLVEnlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Sept. 24 , 2024 (GLOBE NEWSWIR
Enlivex Therapeutics has announced that the Data and Safety Monitoring Board (DSMB) has approved a recommendation to advance to Phase II of its Phase I/II trial for Allocetra in patients with moderate to severe knee osteoarthritis. The Phase I safety run-in demonstrated a favorable safety profile, with no serious adverse reactions reported. The upcoming Phase II stage will involve a double-blind, randomized evaluation comparing Allocetra injections to a placebo, focusing on joint pain and function over time. The study aims to address the significant need for effective osteoarthritis treatments.
Read more →ENLVENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 31, 2024 Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders (the “
Enlivex Therapeutics Ltd. has announced its upcoming Annual General Meeting of Shareholders scheduled for October 31, 2024. Key agenda items include the election of board members, approval of option extensions, and compensation policies for executives. Shareholders of record as of September 16, 2024, are eligible to vote on the proposals which aim to enhance corporate governance. The company's management will present its consolidated financials for the previous year during the meeting.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
Enlivex Therapeutics Ltd. released its condensed consolidated financial statements for the periods ending June 30, 2024, showing significant financial challenges. The company reported a net loss of $3,096K for the latest quarter, contributing to a total loss of $7,236K for the first half of 2024. Cash and cash equivalents did increase to $4,166K, thanks to capital-raising efforts, yet total assets fell significantly compared to the previous year. The absence of revenues and high operating expenses raise concerns about the company's financial stability moving forward.
Read more →ENLV▲ +5.1%on this news
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis First study of Allocetra TM in psoriatic arthritis, a chronic inflammato
Enlivex Therapeutics has received regulatory approval from the Israeli Ministry of Health to begin a Phase I clinical trial for its investigational therapy, Allocetra, in patients suffering from psoriatic arthritis. This trial will evaluate the safety and tolerability of Allocetra following joint injection in patients who are unresponsive to conventional treatments. With a focus on patients with unmet medical needs, the study aims to recruit six participants, marking a significant step in exploring new immunotherapeutic options for this condition.
Read more →ENLVEnlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra TM in up to 46 Patients with Thumb Osteoarthritis First patient dosed with Allocetra TM in thumb
Enlivex Therapeutics has announced the dosing of the first patient in a Phase I/II trial of AllocetraTM for thumb osteoarthritis. This trial, comprised of two stages, aims to evaluate the efficacy and safety of the treatment. The initial safety run-in phase will precede a double-blind randomized stage. Despite being in early stages, the swift enrollment following regulatory approval marks a positive development for the company in addressing unmet needs in this condition.
Read more →ENLVJoin Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 Ness-Ziona, Israel
Enlivex Therapeutics is hosting a live investor webinar on June 25, 2024, featuring CEO Dr. Oren Hershkovitz. The session will discuss the promising interim data from a Phase I/II trial of the company's product candidate, Allocetra, for end-stage knee osteoarthritis. Results showed significant pain reduction in patients awaiting knee-replacement surgery. The webinar will also cover updates on clinical programs and financial status following a recent capital raise.
Read more →ENLVEnlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-r
Enlivex Therapeutics announced a positive interim data readout from a Phase I/II trial evaluating Allocetra in patients with end-stage knee osteoarthritis. The study involved nine patients who received a single injection of Allocetra, resulting in a substantial 64% average reduction in reported pain after three months. Notably, 89% of participants reported improvements, with one-third achieving complete pain relief. The treatment also reduced the need for knee-replacement surgery, emphasizing its potential as a viable alternative for patients with severe arthritis. Recruitment and long-term follow-up for the trial are ongoing.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDA
Enlivex Therapeutics Ltd. released its condensed consolidated financial statements for the three months ending March 31, 2024. The report indicated a net loss of $4.14 million, which is a reduction from the previous year's loss of $7.22 million. The company's total assets decreased to $31.05 million as compared to $36.83 million at the end of December 2023. Enlivex continues to face challenges, including a lack of revenue generation and ongoing accumulated losses, which may hinder future development and operational capabilities.
Read more →ENLV▲ +8.1%on this news
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis First study of Allocetra TM in thumb osteoarthriti
Enlivex Therapeutics has received regulatory authorization from the Israeli Ministry of Health to initiate a Phase I/II clinical trial for Allocetra in patients with basal thumb osteoarthritis. This investigator-initiated trial, led by Dr. Amir Oron, will evaluate Allocetra's efficacy, safety, and tolerability. It consists of two stages, beginning with a safety run-in followed by a randomized placebo-controlled segment. The study aims to recruit up to 46 patients and seeks to provide a disease-modifying treatment for this common condition.
Read more →ENLV▼ -5.1%on this newsshared move
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has closed a registered direct offering valued at up to $15 million, involving 3,571,429 ordinary shares and clinical milestone-linked warrants. The offering was made to a healthcare-focused institutional investor at a purchase price of $1.40 per share. The company plans to use the net proceeds for working capital and general corporate purposes. While the offering indicates strong investor interest, the potential exercise of warrants is uncertain, and the company's success hinges on forthcoming clinical trial results.
Read more →ENLVEnlivex Therapeutics Announces up to $15 Million Registered Direct Offering Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in
Enlivex Therapeutics has announced a registered direct offering with a healthcare-focused institutional investor, totaling up to $15 million. The transaction includes the sale of 3,571,429 ordinary shares at $1.40 each, along with clinical milestone-linked warrants. The offering is expected to generate approximately $5 million upfront, with additional potential proceeds of $10 million upon the exercise of the warrants. The closing of the offering is anticipated on or around May 29, 2024, subject to customary conditions.
Read more →ENLV▲ +15.3%on this news
Enlivex CEO Issues Letter to Shareholders - Perspectives on Recent Events Nes-Ziona, Israel
Enlivex Therapeutics CEO Oren Hershkovitz addressed shareholders about the company's progress with AllocetraTM, a macrophage reprogramming immunotherapy. He highlighted successful patient outcomes from previous studies, including critical cases of COVID-19 and rare bone disease. However, he acknowledged challenges in interpreting data from a recent sepsis Phase II trial due to a higher risk profile for AllocetraTM patients. Looking ahead, Enlivex is optimistic about the potential of AllocetraTM in addressing sepsis and knee osteoarthritis, with several clinical trials underway.
Read more →ENLVEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics has announced the dosing of the first two patients in its Phase I/II trial evaluating Allocetra for moderate to severe knee osteoarthritis. The trial is designed in two stages: an open-label safety run-in followed by a double-blind randomized stage. The company aims to assess the safety and efficacy of Allocetra, particularly focusing on joint pain and function over a year. With over 300 million individuals affected globally by osteoarthritis, the need for effective treatments is critical.
Read more →ENLV▲ +11.5%on this news
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis Nes-Ziona, Israel
Enlivex Therapeutics Ltd. announced that its randomized, controlled Phase I/II trial for Allocetra has received authorization from the Danish Medicines Agency. This trial will assess the safety and efficacy of Allocetra in up to 160 patients with moderate to severe knee osteoarthritis, marking the first European regulatory approval for this study. The multi-center trial includes a safety run-in phase followed by a double-blind, placebo-controlled stage. The company expects to initiate the second randomized stage after the safety run-in, pending independent confirmation from the Data and Safety Monitoring Board.
Read more →ENLV▼ -54%on this newsshared move
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Enlivex Therapeutics Ltd. will host a webcast on April 12, 2024, to discuss the topline results of its Phase II trial evaluating Allocetra™ in patients with sepsis. The trial enrolled 120 patients, and Enlivex's leadership will present the findings followed by a Q&A session. Allocetra™ is designed to reprogram macrophages to help rebalance the immune system, targeting severe medical conditions such as sepsis.
Read more →ENLV▼ -54%on this newsshared move
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis Analysis of eligible 1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol
Enlivex Therapeutics Ltd. announced positive topline results from its Phase II trial evaluating Allocetra for treating sepsis in 120 patients. The study, conducted in multiple countries, indicated a favorable safety profile and potential efficacy, particularly among high-risk patients with sepsis due to urinary tract infections. Despite the encouraging results, the randomization biases posed challenges in analyzing the treatment's relative effectiveness across different patient subgroups. Enlivex plans to review further biomarker data and may pursue additional studies focusing on high-risk UTI populations.
Read more →ENLV▲ +5.5%on this news
ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consoli
Enlivex Therapeutics Ltd. has released its financial statements for the year ending December 31, 2023. An independent audit confirms the financial position and results of operations were presented fairly, with the company maintaining effective internal controls. However, the audit also highlighted ongoing operating losses and dependency on raising additional funds for continued operations. Management forecasts liquidity requirements to be satisfied over the next 12 months, despite the current cash flow challenges.
Read more →ENLVEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has announced the issuance of a new U.S. patent covering its immunotherapy product candidate, Allocetra. This patent, numbered US 11,883,429, is expected to enhance the company's intellectual property protection in the U.S. market. Allocetra is designed as a universal cell therapy aimed at reprogramming macrophages to their homeostatic state, which is essential for immune system regulation. The news reflects significant progress in the company’s efforts to advance its clinical-stage product.
Read more →ENLVEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis Second
Enlivex Therapeutics has announced that the Israeli Ministry of Health has authorized the initiation of a multi-country Phase I/II clinical trial for Allocetra, a therapy targeting moderate to severe knee osteoarthritis. The trial will involve up to 160 patients and will assess both the safety and efficacy of Allocetra through a randomized and controlled study design. The development of Allocetra represents a shift in focus towards the treatment of inflammatory diseases within Enlivex's portfolio, potentially providing a new approach to managing osteoarthritis as well as other conditions characterized by macrophage dysregulation.
Read more →ENLV▲ +12%on this news· ran to +106% by day 3
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sep
Enlivex Therapeutics has announced the completion of enrollment for its Phase II trial of Allocetra, a therapy for patients with sepsis. The study, which involved 120 patients across multiple medical centers, aims to evaluate the efficacy of Allocetra alongside standard care. Given the lack of approved therapies for sepsis and the high mortality rate associated with the condition, this trial represents a significant step forward for Enlivex. Top-line data from the trial is anticipated by the end of the first quarter of 2024.
Read more →ENLV▼ -7.9%on this news
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CO
Enlivex Therapeutics Ltd. has released its condensed consolidated financial statements for the periods ended September 30, 2023, and 2022. The company reported a significant decrease in cash and cash equivalents, falling from approximately $50 million in December 2022 to around $2 million by September 2023. In addition, Enlivex experienced a net loss of $19.973 million in 2023, with increases in operating expenses observed in both research and development, as well as general and administrative areas. The overall asset value is down, highlighting challenges in financial stability.
Read more →ENLVENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on
Enlivex Therapeutics Ltd. is holding its Annual General Meeting (AGM) of Shareholders on October 26, 2023. Shareholders recorded as of September 18, 2023, are entitled to attend and vote on key issues, including board elections and equity grants. Management representatives will review the financial performance for the year ended December 31, 2022. Voting can be done by proxy or in person at the meeting, with specific procedures outlined for beneficial owners and TASE members.
Read more →ENLV▼ -12.7%on this newsshared move
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considere
Enlivex Therapeutics Ltd. announced a strategic reprioritization plan alongside its financial results for Q2 2023. The company aims to increase its focus on inflammatory and autoimmune indications, evidenced by the recent initiation of a clinical program in osteoarthritis. Additionally, Enlivex reported a net loss of $14 million for the first half of 2023, down from $18.1 million in the previous year, and reiterated that its existing cash is sufficient to fund operations through the end of 2025. Notably, the company plans to reduce its workforce by about 50% as part of its restructured strategy.
Read more →ENLVEnlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Enlivex Therapeutics Ltd. is set to present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City on September 12, 2023. The company will provide updates on Allocetra™, its investigational cell therapy aimed at reprogramming macrophages to restore immune balance in life-threatening conditions. This presentation signifies a crucial opportunity for Enlivex to connect with potential investors and highlight its innovative therapeutic approaches. However, the clinical-stage nature of its product development and associated risks of failure remain pertinent concerns.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
Enlivex Therapeutics Ltd. reported its condensed consolidated financial statements for the periods ending June 30, 2023, and December 31, 2022. The company's total assets decreased from $67,642 thousand to $53,028 thousand, mainly due to a substantial drop in cash reserves. Enlivex has not generated any revenue during these periods and has continued to incur operating losses, resulting in a cumulative net loss of $97,035 thousand. The firm remains focused on its research and development efforts related to its universal cell therapy, AllocetraTM, despite the financial challenges it faces.
Read more →ENLVEnlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with CO
Enlivex Therapeutics has published clinical data from Phase I/II trials evaluating Allocetra for treating Acute Respiratory Distress Syndrome (ARDS) in patients with COVID-19, demonstrating a strong safety profile and improved patient outcomes. The study indicated rapid resolution of ARDS and successful reduction of elevated inflammation markers among the treated patients. The findings were peer-reviewed and published in Frontiers in Immunology, further supporting the therapeutic potential of Allocetra. Enlivex plans to explore partnering opportunities to continue development of Allocetra for ARDS.
Read more →ENLVEnlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra In Patients With Sepsis Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has announced the dosing of the first patient under an amended protocol in its Phase II trial evaluating Allocetra for sepsis. The modification allows for higher SOFA score inclusion, facilitating the recruitment of patients with more severe sepsis. Additionally, the new protocol consolidates the trial structure from four cohorts to two, comprising treatment and placebo groups. The company's CEO indicated that they expect to have top-line data available by Q1 2024, in line with previous timelines.
Read more →ENLVEnlivex Announces First Quarter 2023 Financial Results and Provides a Business Update Enrollment of patients in the Phase I/II evaluating Allocetra in combination with chemotherapy in patients with peritoneal metastases
Enlivex Therapeutics reported its financial results for the first quarter of 2023, detailing a decrease in net loss to $7.2 million. The company's research and development expenses rose due to clinical study costs, while its general and administrative expenses saw a slight decline. Enlivex emphasized its innovative cell therapy, Allocetra, aimed at reprogramming macrophages to combat severe health conditions, and indicated strong cash reserves to support operations through 2025.
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDA
Enlivex Therapeutics Ltd. reported its financial results for the first quarter ending March 31, 2023. The company observed a decline in cash equivalents and an increased operational loss when compared to the same period in 2022. The accumulated deficit has reached $90,243 thousand, and notably, the company has not generated any revenue during the quarter. This amounts to continued financial instability as the company relies heavily on funding for its ongoing research and development efforts.
Read more →ENLVEnlivex to Present at the 2023 Jefferies Healthcare Conference
Enlivex Therapeutics Ltd. announced their participation in the 2023 Jefferies Healthcare Conference, where they will provide an update on their operations and the development of Allocetra™, a cell therapy targeting macrophage reprogramming. The presentation is scheduled for June 9, 2022, and will be accessible via a webcast for 90 days. Allocetra™ is aimed at addressing unmet medical needs by potentially restoring macrophage homeostasis for conditions such as solid cancers and sepsis.
Read more →ENLVEnlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has been selected for an Elevator Pitch Presentation and two poster presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy in Paris, France. The presentations will cover their novel macrophage reprogramming immunotherapy, Allocetra. Allocetra is designed to restore macrophage homeostasis in various diseases, including solid cancers and sepsis. This recognition at an international conference underlines the importance of their research and its potential impact on clinical therapies.
Read more →ENLV▲ +9.1%on this news
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has announced the issuance of a European patent for Allocetra, its macrophage reprogramming immunotherapy. This patent, effective until at least 2037, covers the use of Allocetra in preventing cytokine storms in patients undergoing CAR T-cell therapy. The company is developing Allocetra as a universal off-the-shelf therapy aimed at reprogramming macrophages to restore their homeostatic state, potentially improving outcomes in various severe medical conditions.
Read more →ENLVEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra in Patients Receiving CAR T-Cell Therapy Nes-Ziona, Israel
Enlivex Therapeutics Ltd. has announced that it received a Notice of Allowance for its U.S. patent application regarding Allocetra, a novel cell therapy. This patent covers methods for using Allocetra alongside CAR T-cell therapy, aiming to improve treatment outcomes for patients with various cancers and other serious diseases. The expected issuance of the patent will enhance Enlivex's intellectual property protection through at least 2036, underscoring the potential significance of Allocetra in medical treatment. The company anticipates the patent to be officially granted later in 2023.
Read more →ENLVEnlivex Appoints Andrew Singer to its Board of Directors Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy Former EVP and CFO of Epizyme an
Enlivex Therapeutics appointed Andrew Singer to its Board of Directors, leveraging his over 25 years of experience in biotechnology and corporate finance. Singer emphasized the innovative approach of Enlivex’s Allocetra therapy in reprogramming macrophages, which may address serious medical conditions. The company's leadership anticipates substantial benefits from Singer’s strategic insights as they progress in clinical development. Enlivex is focused on addressing unmet medical needs with its novel immunotherapeutic mechanisms.
Read more →ENLVEnlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates Clinical collaboration with BeiGene announced on
Enlivex Therapeutics Ltd. announced a clinical collaboration with BeiGene to evaluate the combination of Allocetra and tislelizumab for treating advanced solid tumors. The company also provided its full-year 2022 financial results, reporting a net loss of $31 million, attributed to increased clinical and preclinical activity. Despite the losses, Enlivex revealed it has $50.2 million in cash, aiding its ongoing initiatives, including amendments to clinical trials for patients with sepsis and advanced-stage solid tumors. The company remains focused on advancing its immunotherapy strategies amid ongoing evaluations and trials.
Read more →ENLVEnlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors Nes-Ziona, Israel
Enlivex Therapeutics has announced a clinical collaboration with BeiGene to evaluate the safety and efficacy of Allocetra in combination with the PD-1 inhibitor, tislelizumab, for patients with advanced-stage solid tumors. The ongoing Phase I/II trial will adjust its protocol to include this combination and aims to enroll up to 48 patients across two stages. This collaboration could lead to potential advancements in treating difficult-to-treat cancers through innovative immunotherapy strategies. However, the success of these efforts is contingent on future clinical trial outcomes.
Read more →ENLVENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consoli
Enlivex Therapeutics Ltd. has released its financial statements as of December 31, 2022, reflecting a net loss of $31,060. Despite maintaining effective internal controls over financial reporting, the company experienced an increase in total operating expenses and a decrease in total assets compared to the previous year. The independent auditors confirmed the financial statements present a fair view of the company's financial position, although the rising operational costs remain a notable concern.
Read more →ENLVEnlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers Nes-Ziona, Israel
Enlivex Therapeutics has received a positive recommendation from an independent Data and Safety Monitoring Board (DSMB) to continue their Phase I/II clinical trial of Allocetra, combined with chemotherapy for patients with peritoneal metastases from solid tumors. The Israeli Ministry of Health (IMOH) has also cleared the next cohort of the trial following the data review, allowing for dose escalation. Importantly, the initial trial results showed no mortality or significant safety signals, leading to a protocol amendment to increase initial doses in upcoming patient cohorts. This represents a significant step forward for Enlivex in its exploration of Allocetra as a novel treatment option in oncology.
Read more →ENLVEnlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial Nes-Ziona, Israel
Enlivex Therapeutics has received clearance from the Spanish Agency of Medicines and Medical Devices (AEMPS) to expand its Phase I/II clinical trial of Allocetra for patients with advanced solid malignancies. This announcement follows previous approvals from the U.S. FDA and the Israeli Ministry of Health. The trial is designed to evaluate Allocetra's safety and efficacy, particularly in combination with PD1 checkpoint inhibitors. Preliminary results from preclinical studies suggest significant survival benefits, prompting optimism about the treatment's potential impact.
Read more →ENLVEnlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS Nes-Ziona,
Enlivex Therapeutics Ltd. announced the issuance of an Israeli patent for the use of Allocetra to prevent cytokine release syndrome (CRS) associated with CAR T-cell therapy and various infectious diseases. The patent, effective until at least 2037, adds to their intellectual property strategy. Allocetra aims to restore macrophage function, potentially enhancing treatment efficacy for patients experiencing severe cytokine storms. The technology presents significant opportunities in addressing unmet medical needs within immunotherapy.
Read more →ENLVEnlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors Nes-Ziona, Israel
Enlivex Therapeutics announced a positive recommendation from an independent Data and Safety Monitoring Board (DSMB) following their review of the Phase I/II trial data for Allocetra in patients with advanced solid tumors. The Israeli Ministry of Health (IMOH) has granted regulatory clearance to continue the trial and open additional cohorts. The trial showed no mortalities or adverse safety signals in the first group of patients. The company is set to initiate higher dosing levels in subsequent trial cohorts to further evaluate safety and efficacy.
Read more →ENLVEnlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium Nes-Ziona, Israel
Enlivex Therapeutics has received regulatory authorizations from agencies in France and Belgium to expand its Phase II clinical trial of Allocetra, an immunotherapy for sepsis. The trial, which originally focused on pneumonia-associated sepsis, now aims to include patients with infections from biliary, urinary tract, or abdominal sources. The study is set to enroll 80 to 160 patients and will evaluate the treatment's safety and efficacy, building on positive results from an earlier Phase Ib trial. CEO Hershkovitz highlighted this expansion as a significant regulatory achievement for the company's ongoing research.
Read more →ENLVEnlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update Received frozen-formulation Allocetra IND clearance from The U.S. Food And Drug Administration (FDA) for treatment of patients with ad
Announces Third Quarter 2022 Financial Results and Provides a Business Update Nes-Ziona, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, on December 2, 2022 file
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2022 AND 2021 ENLIVEX THERAPEUTICS LTD. CO
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2022 AND 2021 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTE
Read more →ENLVEnlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignanci es IND filing followed encouraging preclinical studies conducted in collaborati
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogr
Read more →ENLV▲ +6.2%on this news
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Multi-center trial of Allocetra TM in
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Nes-Ziona, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV,
Read more →ENLV▲ +9.5%on this newsshared move
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
Nes-Ziona, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a poster presentation at the 37th Annual Meeting of the Society For Immunotherapy Of Canc
Read more →ENLVEnlivex to Present at the 4th Macrophage-Directed Therapies Summit
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed
Read more →ENLVEnlivex to Present at Upcoming Investor and Media Conferences
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following investor and media conferenc
Read more →ENLV▲ +7.6%on this newsshared move
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022 Currently used cisplati
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Nes-Ziona, Israel, September 12, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: EN
Read more →ENLVEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy Nes-Ziona, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Comp
Read more →ENLVEnlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immun
Read more →ENLV▲ +11.2%on this newsshared move
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial Sepsis Phase II protocol amendments h
Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial Israel, August 24, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
CONSOLIDATED FINANCIAL STATEMENTS OF JUNE 30, 2022 AND DECEMBER 31, 2021 FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2022 AND 2021 CONSOLIDATED FINANCIAL STATEMENTS OF JUNE 30, 2022 AND DECEMBER 31, 2021 FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2022 AND 2021
Read more →ENLVEnlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancers Received Israeli Ministry of Health approval to initiate a Phase I/II trial evaluating Allocetra™ alone and in combination w
Read more →ENLVEnlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors Trial bui
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors - Trial builds on encouraging preclinical studies conducted in co
Read more →ENLV▲ +6.5%on this news
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra Nes-Ziona, Israel, Aug 3, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherap
Read more →ENLVSheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers l First clinical
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers Nes-Ziona, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutic
Read more →ENLV▼ -8.6%on this news
Enlivex to Present at the 2022 Jefferies Healthcare Conference
Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company management will pre
Read more →ENLVEnlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers Trial w
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising Nes-Ziona, Israel, June 6, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasda
Read more →ENLV▲ +6.1%on this news
Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meetin
Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting Nes-Ziona, Israel, May 31, 2022 (GLOBE NEWSWIRE) - Enli
Read more →ENLV▲ +8.5%on this newsshared move
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2022 AND 2021 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDA
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 AND DECEMBER 31, 2021 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2022 AND DECEMBER 31, 2021
Read more →ENLVEnlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical tr
Awarded Its Third Non-Dilutive Israel Innovation Authority Grant Support the Clinical Development of Allocetra in Sepsis Patients Nes Ziona, Israel, May 25, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunothera
Read more →ENLV▲ +7.2%on this newsshared move
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 b
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced the
Read more →ENLVEnlivex to Present at the H.C. Wainwright Global Investment Conference
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that company manag
Read more →ENLVEnlivex Announces Upcoming May Conference Presentations
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will be presenting scientific and clinical overviews in three oral
Read more →ENLVEnlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting Mesothel
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting Nes-Ziona, Israel, May 9, 2022 (GLOBE NEWSWIRE) - Enlivex Therap
Read more →ENLV▼ -8.9%on this newsshared move
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra Nes-Ziona, Israel
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra Nes-Ziona, Israel, May 5, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today
Read more →ENLV▼ -6.2%on this news· ran to -33% by day 3shared move
Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Nes-Ziona, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the acceptance of an abstract for a poster presentation at the upcoming 2022 American Soci
Read more →ENLVEnlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra Ahead of Schedule, and Provides Strategic & Business Updates Development of frozen formulation Allocetra , a p
Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra Ahead of Schedule, and Provides Strategic & Business Updates Nes-Ziona, Israel, April 29, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a c
Read more →ENLVEnlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel, March 8, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today
Read more →ENLVEnlivex Strengthens Management Team with the Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently
Enlivex Strengthens Management Team with the Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical Nes Ziona, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage repro
Read more →ENLV▲ +6.6%on this news
Enlivex to Detail the Application of its Innovative Macrophage Reprogramming Cell Therapy to Unmet Needs in Oncology at the 11th Annual LifeSci Partners Corporate Access Event
** Management to participate in a panel discussion: “Innovative Approaches to Cell Therapy for Oncology,” which is taking place on Friday, January 7th, at 8:30 AM ET ** ** Panelists to discuss how their cell-based technologies, including, CAR-T cells, CAR-NK cells, TCR-T cells,
Read more →ENLVEnlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece Nes-Ziona, Israel
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece Nes-Ziona, Israel, December 13, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage m
Read more →ENLV▲ +5.8%on this news
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece Nes-Ziona, Israel
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece Nes-Ziona, Israel, December 7, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today ann
Read more →ENLVEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for U.S. Covering the Treatment of Sepsis Patients with Nes-Ziona, Israel, December 6, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today
Read more →ENLV▼ -7.3%on this news
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating Allocetra TM in severe and critical COVID-19 patients with
Announces Third Quarter 2021 Financial Results and Provides a Business Update dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with authorization to expand ongoing sepsis and COVID-19 trials into Spain design
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020 ENLIVEX THERAPEUTICS LTD. CO
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTE
Read more →ENLVSpanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain Nes Ziona, Israel
Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain Nes Ziona, Israel, November 10, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage repr
Read more →ENLVSpanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain Nes Ziona, Israel
Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Nes Ziona, Israel, November 4, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanis
Read more →ENLVEnlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
Publication follows the Israeli Ministry of Health’s appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines Nes-Ziona, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clin
Read more →ENLVEnlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for Israeli Covering Allocetra Derived from Pooled Donor Cells Nes-Ziona, Israel, October 5, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company ta
Read more →ENLVEnlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis Data published in Frontiers in Immunology show a robust safety
Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis published in Frontiers in Immunology show a robust safety profile and substantial improvements in state of organ failure, duratio
Read more →ENLVENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON NOVEMBER 4, 2021 Notice is hereby given that an Annual and Extraordinary General Meeting of the shareholders (the " Meeting
ENLIVEX THERAPEUTICS LTD. ANNUAL AND EXTRAORDINARY GENERAL MEETING OF Notice is hereby given that an Annual and Extraordinary General Meeting of the shareholders (the "Meeting") of Enlivex Therapeutics Ltd. (the "Company") will be held at the offices of the Company at 14 Eins
Read more →ENLV▼ -7.1%on this newsshared move
Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021
Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the Reuters Events' Cell &
Read more →ENLVEnlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS Top-line data from the randomized, multi-center trial are expected in Q2-
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS the randomized, multi-center trial are expected in Q2-2022 Nes-Ziona, Israel, September 22, 2021 (GLOBE NEWSWIRE) - Enlivex Thera
Read more →ENLVEnlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that C
Read more →ENLV▲ +13%on this news
Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Nes Ziona, Isr
Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Nes Ziona, Israel, August 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeu
Read more →ENLV▲ +18%on this news· ran to +28% by day 3
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update Top-line results from Phase IIb sepsis trial expected in Q2 2022 Phase IIb trial in severe and critical COVID-19 patients planned for
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update Nes Ziona, Israel, August 9, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announce
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2021 AND 2020 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2021 AND 2020 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 AN
Read more →ENLV▲ +11.8%on this news
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer,
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix
Read more →ENLVEnlivex to Present at the Improvate Life-Saving Technologies International Conference 2021
Nes Ziona, Israel, July 21, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide an interview at, the
Read more →ENLVEnlivex to Present at the ARDS Drug Development Summit 2021
Nes Ziona, Israel, July 14, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company will participate in, and present at, the ARDS Drug Development Summit on
Read more →ENLVEnlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant New cGMP manufacturing plant designed to support additional clinical- and initial commercial-scale production of Allocetra Ne
Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant New cGMP manufacturing plant designed to support additional clinical- and initial commercial-scale production of Allocetra Nes Ziona, Israel, July 12, 2021 (GLOBE NEWSWIRE) -- Enliv
Read more →ENLVEnlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium
Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer
Read more →ENLVEnlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer Nes-Zio
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) - Enlivex The
Read more →ENLVEnlivex to Present at the Jefferies 2021 Virtual Healthcare Conference
Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual Healthcare Conference
Read more →ENLVEnlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy Nes-Ziona, Israel
Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy Nes-Ziona, Israel, June 1, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macr
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2021 AND 2020 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Pa
ENLIVEX THERAPEUTICS CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2021 AND DECEMBER 31, 2020 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2021 AND 2020 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets F-2 Condensed Co
Read more →ENLVEnlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a cl
Read more →ENLVEnlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra in Combination with Immune Checkpoint Inhibitors Collaboration aims to evaluate the potential of Allocetra in com
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra in Combination with Immune Checkpoint Inhibitors Collaboration aims to evaluate the potential of Allocetra in combination with immune-checkpoint inhibitors in solid cance
Read more →ENLVEnlivex Announces Upcoming Virtual Investor Conference Participations
Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the following investor conferences: 2nd Annual
Read more →ENLVEnlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies Nes-Ziona, Israel
Receives Notice of Allowance for Japanese Patent Application the use of Allocetra in Combination with CAR-T Therapies Israel, March 8, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy compa
Read more →ENLVEnlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors -- Collaboration aims to evaluate the potential of Allocetra in comb
and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint -- Collaboration aims to evaluate the potential of Allocetra in combination with immune-checkpoint inhibitors in solid cancer patients that do no
Read more →ENLVEnlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy Nes-Ziona, Israel, February 22, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy compan
Read more →ENLVEnlivex Announces Exercise of Underwriter's Option to Purchase Additional Shares Nes Ziona, Israel
Exercise of Underwriter's Option to Purchase Additional Shares Feb. 18, 2021, Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today annou
Read more →ENLVEnlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy Nes-Ziona, Israel
Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis and GvHD Using Allocetra Nes-Ziona, Israel, February 16, 2021 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Comp
Read more →ENLVEnlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares Nes Ziona, Israel
Enlivex Announces Closing of Previously Announced Bought Offering of Approximately $46.0 Million Ordinary Shares Feb. 12, 2021, Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients
Read more →ENLVEnlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that due to demand, th
Read more →ENLVEnlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that it has entered in
Read more →ENLVEnlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update Phase II (16 patients treated, 9/16 (56%) with severe ill
Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update Nes Ziona, Israel, February 3, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a
Read more →ENLVEnlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the H.C. Wainwright BioConnect 2021 Virtual Conf
Read more →ENLVEnlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv - Comparison of 10 Allocetra TM -treated patients with 37 matched controls showed significant positive responses in sta
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv - Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in
Read more →ENLVEnlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy Nes Ziona, Israel
Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy Ziona, Israel, December 7, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today announced that the China National Intellectual Pr
Read more →ENLVEnlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Nes Ziona, Israel
Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Nes Ziona, Israel, December 3, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, t
Read more →ENLVEnlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra * Significant short and long-term clinical improvement for a hospitalized patient with a ra
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment Nes Ziona, Israel
Read more →ENLVEnlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of Directors * Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion
Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of Directors Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 * Ziona, Israel,
Read more →ENLVEnlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright's 6 th Annual Israel Conference Nes Ziona, Israel
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright's 6th Annual Israel Conference Nes Ziona, Israel, November 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company
Read more →ENLVEnlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, and Ulcerative Colitis with Allocetra Immunotherapy Nes-Ziona, Israel
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, and Ulcerative Colitis with Allocetra Immunotherapy Nes-Ziona, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Read more →ENLVEnlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients Nes Ziona, Israel
Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients Nes Ziona, Israel, November 3, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stag
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2020 AND DECEMBER 31, 2019 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2020 AND 2019 ENLIVEX THERAPEUTICS LTD. CO
CONSOLIDATED FINANCIAL STATEMENTS OF SEPTEMBER 30, 2020 AND DECEMBER 31, 2019 FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2020 AND 2019 CONSOLIDATED FINANCIAL STATEMENTS OF SEPTEMBER 30, 2020 AND DECEMBER 31, 2019 FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTE
Read more →ENLVEnlivex to Host COVID-19 Webinar: The Staging of a New Disease and Its Implications for Treatment Options, with Mount Sinai Key Opinion Leader * Findings and Analyses On 68,000 COVID-19 Patients Discussed in the Webinar
Enlivex to Host COVID-19 Webinar: The Staging of a New Disease and Its Implications for Treatment Options, with Mount Sinai Key Opinion Leader Findings and Analyses On 68,000 COVID-19 Patients Discussed in the Webinar on Thursday, November 5th @ 10amET * Ziona, Israel, October
Read more →ENLVEnlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Nes Ziona, Israel
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients Nes Ziona, Israel, October 22, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 AND DECEMBER 31, 2019 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2020 AND 2019 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 AND DECEMBER 31, AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2020 AND 2019 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2020 AND DEC
Read more →ENLVEnlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients Nes Ziona, Israel
Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients Nes Ziona, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company
Read more →ENLVEnlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition Nes Ziona, Israel
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition Nes Ziona, Israel, October 1, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today reported positive t
Read more →ENLVEnlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy Nes-Ziona, Israel
Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy Israel, September 16, 2020 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issue
Read more →ENLVEnlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy Nes-Ziona, Israel
Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy Israel, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new
Read more →ENLVEnlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure Nes Ziona, Israel
Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure Nes Ziona, Israel, Aug. 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today an
Read more →ENLVEnlivex Announces a new publication “Apoptotic cell therapy for cytokine storm associated with acute severe sepsis” in Cell Death & Disease, a Nature Research Journal
- Data show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model Nes Ziona, Israel, July 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced t
Read more →ENLVEnlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy Nes-Ziona, Israel
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issue
Read more →ENLVEnlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
Nes Ziona, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 8:
Read more →ENLVEnlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting - Explora
Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting - Exploratory endpoint analyses demonstrated Allocetra's potential therape
Read more →ENLVENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON JUNE 24, 2020 Notice is hereby given that an Annual and Extraordinary General Meeting of the shareholders (the " Meeting ")
AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS is hereby given that an Annual and Extraordinary General Meeting of the shareholders (the "Meeting") of Enlivex Therapeutics Ltd. (the "Company") will be held, subject to applicable laws and regulations relating to restrictions
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020 AND DECEMBER 31, 2019 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDA
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020 AND DECEMBER 31, AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2020 AND 2019 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2020 AND DECEMBER
Read more →ENLVEnlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients Nes Ziona, Israel
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients May 06, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator
Read more →ENLVEnlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials Nes Ziona, Israel
Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials Ziona, Israel, April 13, 2020 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Isr
Read more →ENLVEnlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis - Final Analysis Comparing 10 Allocetra TM -Treated Patients with 37 Matched Control
Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis - Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure,
Read more →ENLVEnlivex Therapeutics Closes $16.75 Million Registered Direct Offering
Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain accredited and healthcare-focused institutional in
Read more →ENLVEnlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South KoreaRegarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra TM as Tre
Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South KoreaRegarding Submission of Proposal to the Korean Authorities for Potential Use of AllocetraTM as Treatment of Patients with Coronavirus Disease (COVID-19) Pat
Read more →ENLVEnlivex Therapeutics Announces $16.75 Million Registered Direct Offering
Nes-Ziona, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain accredited and healthcare-focused institutional investors, including
Read more →ENLVEnlivex Therapeutics Closes $8.0 Million Registered Direct Offering Nes-Ziona, Israel
Therapeutics Closes $8.0 Million Registered Direct Offering Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain i
Read more →ENLVEnlivex Therapeutics Announces Plan for Increased Production Capacity of Allocetra TM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure Nes-Ziona, Israel
Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure Nes-Ziona, Israel, February 24, 2020 - Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage
Read more →ENLVEnlivex Therapeutics Announces $8.0 Million Registered Direct Offering
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offer
Read more →ENLVEnlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares
Nes Ziona, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (“Enlivex” or the “Company”) (NASDAQ: ENLV) today announced that it has withdrawn its previously announced proposed underwritten public offering of ordinary shares due to market conditions. The Compan
Read more →ENLVEnlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares
Nes Ziona, Israel, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (“Enlivex” or the “Company”) (NASDAQ: ENLV) today announced that, subject to market and other conditions, it intends to offer and sell ordinary shares (the “Shares”) in an underwritten public offering
Read more →ENLVEnlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis
Nes Ziona, Israel, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today reported completion of patient recruitment into the Company’s Phase Ib clinical trial in patients with severe sepsis. The study was desig
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2019, AND DECEMBER 31, 2018 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2019 AND 2018 ENLIVEX THERAPEUTICS LTD. C
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2019, AND DECEMBER AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2019 AND 2018 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30,
Read more →ENLVEnlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference
Nes-Ziona, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation and host 1x1 meetings at the 10th Annual Jefferies 2019 London Healthc
Read more →ENLVEnlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis -- Interim Analysis Comparing Allocetra-Treated Patients with 37 Sever
Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis -- Interim Analysis Comparing Allocetra-Treated Patients with 37 Severe Sepsis Patients with Equivalent Source of Infection and
Read more →ENLVEnlivex Announces Appointment of New Chief Executive Officer
Nes-Ziona, Israel, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced the appointment of Dr. Oren Hershkovitz as Chief Executive Officer, effective November 16, 2019. Dr. Hershkovitz served for nearly a decade in
Read more →ENLVEnlivex Therapeutics To Present At The 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
Nes-Ziona, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the 21st Annual Global Investment Conference, sponsored by H.C. Wai
Read more →ENLVEnlivex Therapeutics Announces Positive Outcome From Safety Committee's Review Of Six Patients With Severe Sepsis Patients; Enrollment Of Last Study Cohort Approved Nes Ziona, Israel
Enlivex Therapeutics Announces Positive Outcome From Safety Committee's Review Of Six Patients With Severe Sepsis Patients; Enrollment Of Last Study Cohort Nes Ziona, Israel, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunothe
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2019 AND DECEMBER 31, 2018 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2019 AND 2018 ENLIVEX THERAPEUTICS LTD. CONDENSED CON
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2019 AND DECEMBER 31, AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2019 AND 2018 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2019 AND DECEMBER 31, AND FOR THE THREE AND SIX MONTH PERIODS EN
Read more →ENLVImmunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange The Company's shares, which currently trade on NASDAQ, will be dual-listed on the Tel Aviv Stock Exchange (TASE) starting on
Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange The Company's shares, which currently trade on NASDAQ, will be dual-listed on the Tel Aviv Stock Exchange (TASE) starting on July 22, 2019, under the symbol ENLV July 16, 2019 - Enlivex Therap
Read more →ENLVEnlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients
Nes Ziona, Israel, June 06, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today provided a clinical update on the positive safety profile of its off-the-shelf cell therapy, AllocetraTM, in the first three severe sepsis
Read more →ENLVEnlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare Conference
Nes-Ziona, Israel, May 30, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the Jefferies Global Healthcare 2019 conference being held in New Yo
Read more →ENLVENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2019 AND DECEMBER 31, 2018 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2019 AND 2018 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDA
ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2019 AND DECEMBER 31, AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2019 AND 2018 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2019 AND DECEMBER
Read more →ENLVENLIVEX THERAPEUTICS TO PRESENT AT THE 2019 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
Nes-Ziona, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the H.C. Wainwright Global Life Sciences 2019 conference being held
Read more →ENLVEXECUTION VERSION
Article I DEFINITIONS 1 1.1 Definitions 1 Article II PURCHASE AND SALE 3 2.1 Closing 3 2.2 Closing Deliveries. 3 Article III REPRESENTATIONS AND WARRANTIES 4 3.1 Incorporation of Certain Representations and Warranties from Merger Agreement 4 3.2 Representations and Warranties of
Read more →ENLVBioblast Announces Effectiveness of Eight to One Reverse Split Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on
Bioblast Announces Effectiveness of Eight to One Reverse Ordinary Shares Will Begin Trading Basis on March 6, 2019 Tel Aviv, Israel, - March 6, 2019 - Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effecti
Read more →ENLVBIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS General Notice is hereby given that an Extraordinary General Meeting of the Shareholders of Bioblast Pharma Ltd. (the " Company " or " Biob
BIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING Notice is hereby given that an Extraordinary General Meeting of the Shareholders of Bioblast Pharma Ltd. (the "Company" or "Bioblast") will be held on March 17 February 22, 2019, at noon Israel Time, at the offices
Read more →ENLVASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this " Agreement ") is made as of
ASSET PURCHASE AGREEMENT AGREEMENT (this "Agreement") is made as of February 15, 2019, by and among Seelos Therapeutics, Inc., a Nevada corporation ("Buyer"), and Bioblast Pharma, Ltd., an Israeli corporation ("Seller"). Buyer and Seller may be referred to herein collectively
Read more →ENLVUnaudited Financial Information as of and for the Six Months Ended
Information as of and for the Six Months Ended June 30, 2018 In compliance with Nasdaq Stock Market Rule 5250(c)(2), Bioblast Pharma Ltd. (the "Company") hereby furnishes its unaudited consolidated statement of operations for the six months ended June 30, 2018 and its unaudite
Read more →ENLVto such report, and copies of which are attached as Annexes A and B, respectively, to the proxy statement being mailed together with this Notice. (i) To approve a reverse share split of the Company's ordinary shares, par
OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS On November 21, 2018, Bioblast Pharma Ltd. (the "Company", or "Bioblast") furnished to the Securities and Exchange Commission (the "SEC") a notice of Annual and Extraordinary General Meeting of Shareholders (the "
Read more →ENLVto the 6-K Report. 2 The Transaction will not be completed if Item No. 1 is not approved. 2. To re-appoint Kost, Forer, Gabbay & Kasierer (a member of Ernst & Young Global) as the Company's independent registered public
BIOBLAST PHARMA LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL Notice is hereby given that an Annual and Extraordinary General Meeting of the Shareholders of Bioblast Pharma Ltd. (the "Company" or "Bioblast") will be held on December 26, 2018, at 10:00 am Israel Time, at the
Read more →ENLVEXECUTION VERSION AGREEMENT AND PLAN OF MERGER By and Among BIOBLAST PHARMA LTD. TREBLAST LTD. AND ENLIVEX THERAPEUTICS LTD. Dated as of
AGREEMENT AND PLAN OF MERGER BIOBLAST PHARMA LTD. ENLIVEX THERAPEUTICS LTD. Dated as of November 19, 2018 Page Article I The Merger 1 Section 1.01 The Merger 1 Section 1.02 Closing 2 Section 1.03 Effective Time 2 Section 1.04 Effects 2 Section 1.05 Articles of Association
Read more →ENLVBioblast Pharma Ltd. Corporate and Management Update Tel Aviv, Israel and New York, New York
Bioblast Pharma Ltd. Corporate and Management Tel Aviv, Israel and New York, New York, July 26, 2018 - Bioblast Pharma Ltd. (Nasdaq: ORPN) is providing an update on business development activities as well as notice of an organization change that affects members of the board an
Read more →ENLVBIOBLAST PHARMA LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS Notice is hereby given that an Annual and Extraordinary General Meeting of the Shareholders of Bioblast Pharma Ltd. (" Company "
BIOBLAST PHARMA LTD. NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL Notice is hereby given that an Annual and Extraordinary General Meeting of the Shareholders of Bioblast Pharma Ltd. ("Company") will be held on December 21, 2017, at 10:00 am Israel Time, at the offices of the Co
Read more →ENLVBioblast Pharma Reports Third Quarter 2017 Financial Results Tel Aviv, Israel
Bioblast Pharma Reports Third Quarter 2017 Financial Results Tel Aviv, Israel, - November 2, 2017 - Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 3
Read more →ENLVBioblast Announces Effectiveness of Five to One Reverse Split Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on
Announces Effectiveness of Five to One Reverse Shares Will Begin Trading on a Split-Adjusted on September 25, 2017 Tel Aviv, Israel, - September 25, 2017 - Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the eff
Read more →ENLVBIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS Notice is hereby given that an extraordinary general meeting of the shareholders of Bioblast Pharma Ltd. (" Company ") will be held on
BIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING Notice is hereby given that an extraordinary general meeting of the shareholders of Bioblast Pharma Ltd. ("Company") will be held on September 18, 2017, at 10:00 am Israel time, at the offices of the Company's couns
Read more →ENLVInvestor Contact JSB-Partners Contact Matthew P. Duffy Wolfgang Stoiber Managing Director Managing Director LifeSci Advisors LLC JSB-Partners Matthew@LifeSciAdvisors.com wstoiber@jsb-partners.com Phone: 212-915-0685 Phon
Investor Contact JSB-Partners Contact Matthew P. Duffy Wolfgang Stoiber Managing Director Managing Director LifeSci Advisors LLC JSB-Partners Matthew@LifeSciAdvisors.com wstoiber@jsb-partners.com Phone: 212-915-0685 Phone: 978-697-9753 Bioblast Pharma Reports Second Quarter 201
Read more →ENLVINVESTOR CONTACT: Matthew P. Duffy Managing Director LifeSci Advisors, LLC Telephone: 212-915-0685 Matthew@LifeSciAdvisors.com Bioblast Pharma Reports First Quarter 2017 Financial Results Tel Aviv, Israel
LifeSci Advisors, LLC Telephone: 212-915-0685 Matthew@LifeSciAdvisors.com Bioblast Pharma Reports First Quarter 2017 Financial Results Aviv, Israel, - May 26, 2017 - Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today
Read more →ENLVINVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC Matthew@lifesciadvisors.com Phone: 212-915-0685 Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders' Equity
LifeSci Advisors LLC Matthew@lifesciadvisors.com Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders' Equity and Minimum Bid Requirements Tel Aviv, Israel, - April 17, 2017 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orph
Read more →ENLVMatthew@lifesciadvisors.com
LifeSci Advisors LLC Matthew@lifesciadvisors.com Pharma Announces Receipt of Notification Regarding Stockholders' Equity Tel Aviv, Israel, - March 10, 2017 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced toda
Read more →ENLVINVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC Matthew@lifesciadvisors.com Phone: 212-915-0685 Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results Tel Aviv, Israel
LifeSci Advisors LLC Matthew@lifesciadvisors.com Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results Tel Aviv, Israel, - February 24, 2017 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today an
Read more →ENLVINVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC Phone: 212-915-0685 Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3) Patients Treated with Tr
LifeSci Advisors LLC Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3) Patients Treated with Trehalose Remained Stable According to a Well-Established Clinical A Recent Natural History Study in The Lancet Neurology in Pa
Read more →ENLVBioblast Pharma Reports Third Quarter 2016 Financial Results Tel Aviv, Israel
Bioblast Pharma Reports Third Quarter 2016 Financial Results Tel Aviv, Israel, - November 29, 2016 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September
Read more →ENLVINVESTOR CONTACT: Matthew P. Duffy Managing Director LifeSci Advisors, LLC Telephone: 212-915-0685 Bioblast Announces Results of Trehalose Clinical Study Pharmacokinetic Study in Healthy Volunteers Demonstrated Trehalose
LifeSci Advisors, LLC Telephone: 212-915-0685 Bioblast Announces Results of Trehalose Study in Healthy Volunteers Demonstrated Trehalose to be Safe and Well Tolerated at Twice the Dose Levels Used in Prior Results Support Weight-Based Dosing Paradigm Tel Aviv, Israel, - Oct
Read more →ENLVBioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy (OPMD) Patients Tel Aviv, Israel
Bioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy (OPMD) Patients Tel Aviv, Israel, - September 12, 2016 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announce
Read more →ENLVBioblast Pharma Reports Second Quarter 2016 Financial Results Tel Aviv, Israel
Bioblast Pharma Reports Second Quarter 2016 Financial Results Tel Aviv, Israel, - August 25, 2016 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2
Read more →ENLVBIOBLAST PHARMA LTD. NOTICE OF ANNUAL GENERAL MEETING OF THE SHAREHOLDERS Notice is hereby given that an Annual General Meeting of the Shareholders of BioBlast Pharma Ltd. (" Company ") will be held on
BIOBLAST PHARMA LTD. NOTICE OF ANNUAL GENERAL MEETING OF THE Notice is hereby given that an Annual General Meeting of the Shareholders of BioBlast Pharma Ltd. ("Company") will be held on August 9, 2016, at 10:00 am Israel Time, at the offices of the Company's counsel (Zysman,
Read more →ENLVBioblast Pharma Updates Corporate Plans Trehalose Phase 2b Trial in Oculopharyngeal Muscular Dystrophy (OPMD) On Track to Commence During the Second Half of 2016 Focus On Trehalose As a Potential Platform Corporate Restr
Pharma Updates Corporate Plans Phase 2b Trial in Oculopharyngeal Muscular Dystrophy (OPMD) Track to Commence During the Second Half of 2016 On Trehalose As a Potential Platform Restructuring and Management Changes: Price, Executive Chairman, will lead the day-to-day operati
Read more →ENLVBioblast Pharma Reports First Quarter 2016 Financial Results New Haven, Connecticut
Bioblast Pharma Reports First Quarter 2016 Financial Results New Haven, Connecticut - May 25, 2016 - Bioblast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31,
Read more →ENLVBIOBLAST PHARMA ANNOUNCES PRICING OF $6.7 MILLION REGISTERED DIRECT OFFERING New Haven, CT
BIOBLAST PHARMA ANNOUNCES PRICING OF $6.7 MILLION REGISTERED DIRECT OFFERING New Haven, CT - March 17, 2016 - BioBlast Pharma Ltd. (Nasdaq: ORPN) (the "Company" or "ORPN") announced that it has entered into definitive securities purchase agreements with two healthcare focused
Read more →ENLVBIOBLAST PHARMA LTD. CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2015 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Consolidated Balance Sheets 2 Consolidated Statements of Operations 3 Consolidated Stateme
BIOBLAST PHARMA LTD. CONSOLIDATED INTERIM FINANCIAL STATEMENTS U.S. DOLLARS IN THOUSANDS Page Consolidated Balance Sheets 2 Consolidated Statements of Operations 3 Consolidated Statements of Changes in Shareholders' Equity 4 Consolidated Statements of Cash Flows 5 Notes to Co
Read more →ENLVBioBlast Pharma Announces Positive Final Results from HOPEMD Phase 2 Open-Label Clinical Study of Trehalose 90mg/mL IV Solution in Oculopharyngeal Muscular Dystrophy (OPMD) New Haven, Connecticut
BioBlast Pharma Announces Positive Final Results from HOPEMD Phase 2 Open-Label Clinical Study of Trehalose 90mg/mL IV Solution in Oculopharyngeal Muscular New Haven, Connecticut - March 16, 2016 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focuse
Read more →ENLVBioBlast Pharma Reports Fourth Quarter and Full Year 2015 Financial Results New Haven, Connecticut
BioBlast Pharma Reports Fourth Quarter New Haven, Connecticut - February 23, 2016 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the fourth quarter and fiscal year ended December 31
Read more →ENLVBIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of the Shareholders of BioBlast Pharma Ltd. (" Company ") will be held on
BIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING Notice is hereby given that an Extraordinary General Meeting of the Shareholders of BioBlast Pharma Ltd. ("Company") will be held on February 24, 2016, at 10:00 a.m. (Israel Time), at the offices of the Company's co
Read more →ENLVBioBlast Pharma Enhances Leadership Team Appoints Industry Veteran, Robert W. Cook, as Chief Financial Officer New Haven, CT
BioBlast Pharma Enhances Leadership Team Appoints Industry Veteran, Robert W. Cook, as Chief Financial Officer New Haven, CT - January 11, 2016 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for pa
Read more →ENLVBIOBLAST
BIOBLAST PHARMA PROVIDES RESEARCH AND NEW HAVEN, Conn., December 9, 2015 -- BioBlast Pharma Ltd. (Nasdaq: ORPN), a clinical-stage biotechnology company developing meaningful therapies for patients with rare and ultra-rare genetic diseases, today provided an update on its resea
Read more →ENLVBioBlast Pharma Reports Third Quarter Financial Results Tel Aviv, Israel
BioBlast Pharma Reports Third Quarter Tel Aviv, Israel November 17, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 30, 2015. BioBlast ended t
Read more →ENLVBioBlast Pharma Strengthens Leadership Team and Announces Key Organizational Changes Significant Evolution of Senior Leadership Team in 2015 Co-Founders Transition Company to Globally-Experienced Executives New Haven, CT
BioBlast Pharma Strengthens Leadership Team and Announces Key Organizational Changes Significant Evolution of Senior Leadership Co-Founders Transition Company to Globally-Experienced Executives New Haven, CT - November 16, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a cli
Read more →ENLVAnnounces Positive Interim Results from HOPEMD Phase 2 Clinical Study of Cabaletta in Oculopharyngeal Muscular
Announces Positive Interim Results from HOPEMD Phase 2 Clinical Study of Cabaletta in Oculopharyngeal Muscular Conference Call and Webcast, 8:30 a.m. New Haven, CT and Tel Aviv, Israel - October 27, 2015 - BioBlast Pharma Ltd., (NasdaqGM: ORPN), a clinical-stage biotechnology
Read more →ENLVBioBlast Pharma Augments Leadership Team Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer New Haven, CT
BioBlast Pharma Augments Leadership Team Appoints Former Aptalis and Novartis Executive, Theresa M. Stevens, as Chief Corporate Development Officer New Haven, CT - October 9, 2015 - BioBlast Pharma Ltd., (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to de
Read more →ENLVBioBlast Pharma Announces Appointment of Tom Dubin, Former Alexion SVP & Chief Legal Officer, to the Board of Directors New Haven, CT
BioBlast Pharma Announces Appointment of Tom Dubin, Former Alexion SVP & Chief Legal Officer, to the Board of Directors New Haven, CT - September 16, 2015 - BioBlast Pharma Ltd., (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful thera
Read more →ENLVBioBlast Granted Patent From USPTO For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA)
BioBlast Granted Patent From USPTO For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) TEL AVIV, Israel, September 14, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it was granted
Read more →ENLVBioBlast Pharma Augments Leadership Team and Establishes U.S. Headquarters in New Haven, Connecticut Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer New Haven, CT
Pharma Augments Leadership Team and Establishes in New Haven, Connecticut Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer New Haven, CT - September 10, 2015 - BioBlast Pharma Ltd., (NasdaqGM: ORPN), a clinical-stage biotechnology company committed
Read more →ENLVBioBlast Pharma Reports Second Quarter Financial Results Tel Aviv, Israel
BioBlast Pharma Reports Second Quarter Tel Aviv, Israel August 21, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2015. BioBlast ended the se
Read more →ENLVBioBlast Pharma Receives Orphan Drug Designation From The European Commission For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA)
BioBlast Pharma Receives Orphan Drug Designation From The European Commission For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) TEL AVIV, Israel, June 29, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company
Read more →ENLVBioBlast Pharma Receives Orphan Drug Designation From The European Commission For Cabaletta For The Treatment Of Oculopharyngeal Muscular Dystrophy
Pharma Receives Orphan Drug Designation From The European Commission For For The Treatment Of Oculopharyngeal Muscular Dystrophy TEL AVIV, Israel, June 25, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company, announced to
Read more →ENLVBioBlast Announces Positive Preclinical Proof-Of-Concept Results Of Its Novel Read-through Platform in Spinal Muscular Atrophy (SMA)
BioBlast Announces Positive Preclinical Proof-Of-Concept Results Of Its Novel Read-through Platform in Spinal Muscular Atrophy (SMA) TEL AVIV, Israel, June 22, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company, announce
Read more →ENLVBioBlast Announces The Start Of A Phase 3 Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) New Pivotal Study Reflects Positive Signals Reported From The Current HOPEMD Study, Which Will Be Closed Out At 2
BioBlast Announces The Start Of A Phase 3 Study For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) New Pivotal Study Reflects Positive Signals Reported From The Current HOPEMD Study, Which Will Be Closed Out At 25 patients TEL AVIV, Israel, June 15, 2015- BioBlast Pha
Read more →ENLVBioBlast Pharma Reports First Quarter Financial Results Tel Aviv, Israel
BioBlast Pharma Reports First Quarter Tel Aviv, Israel May 19, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first quarter ended March 31, 2015. BioBlast ended the first
Read more →ENLVBioBlast Pharma Announces Granting of Fast Track Designation by the FDA for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)
BioBlast Pharma Announces Granting of Fast Track Designation by the FDA for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD) TEL AVIV, Israel, April 9, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company announced
Read more →ENLVBioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of its Cabaletta Platform in Spinocerebellar Ataxia Type 3 (SCA3)
BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of its Cabaletta Platform in Spinocerebellar Ataxia Type 3 (SCA3) TEL AVIV, Israel, March 30, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology co
Read more →ENLVBioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia
BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia TEL AVIV, Israel, March 26, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnol
Read more →ENLVBioBlast Receives IND Clearance to Commence Clinical Trial for Cabaletta for the Treatment of
BioBlast Receives IND Clearance to Commence Cabaletta for the Treatment of OPMD TEL AVIV, Israel, March 12, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that the U.S. Food and Drug Administration
Read more →ENLVBioBlast Pharma Reports Fourth Quarter Financial Results Tel Aviv, Israel - February 17, 201 5 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful
BioBlast Pharma Reports Fourth Quarter Tel Aviv, Israel - February 17, 2015 - BioBlast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, today ann
Read more →ENLVBIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of the Shareholders of BioBlast Pharma Ltd. (" Company ") will be held on Wednesda
BIOBLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING Notice is hereby given that an Extraordinary General Meeting of the Shareholders of BioBlast Pharma Ltd. ("Company") will be held on Wednesday, March 18, 2015, at 10:00 am (Israel Time), at the offices of the Compan
Read more →ENLVBio Blast Announces Key Leadership Changes
Bio Blast Announces Key Leadership Changes TEL AVIV, Israel, February 2, 2015 - Bio Blast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients with rare and ultra-rare genetic diseases, announced key sen
Read more →ENLVEnlivex Granted EU Orphan Drug Designation for Lead Product ApoCell for Graft-Versus-Host Disease
JERUSALEM, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Enlivex Therapeutics (Enlivex), a Hadasit Bio-Holdings ("HBL") (TASE:HDST) (OTCQB:HADSY) portfolio company, today announced that the European Medicines Agency ("EMA") has granted orphan drug status to the Company's lead product candida
Read more →ENLVBio Blast Provides Update on Clinical Trial of Cabaletta for Occulopharyngeal Muscular Dystrophy (OPMD)
Bio Blast Provides Update on Clinical Trial of Cabaletta for Occulopharyngeal Muscular Dystrophy (OPMD) TEL AVIV, Israel, January 8, 2015 - Bio Blast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing meaningful therapies for patients
Read more →ENLVBioBlast Receives Notice of Patent Issuance from USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia
BioBlast Receives Notice of Patent Issuance from USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia AVIV, Israel, December 17, 2014 - Bio Blast Pharma Ltd, (NasdaqGM: ORPN) a clinical-stage biotechnology company committed to developing cl
Read more →ENLVBio Blast Pharma Reports Third Quarter Financial Results Tel Aviv, Israel
Bio Blast Pharma Reports Third Quarter Tel Aviv, Israel - November 21, 2014 - Bio Blast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, today an
Read more →ENLVBio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3
Bio Blast Pharma Receives Orphan Drug From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3 TEL AVIV, Israel, November 19, 2014 - Bio Blast Pharma Ltd. (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing clinically meaning
Read more →ENLVBIO BLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of the Shareholders of Bio Blast Pharma Ltd. (" Company ") will be held on Thursd
BIO BLAST PHARMA LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING Notice is hereby given that an Extraordinary General Meeting of the Shareholders of Bio Blast Pharma Ltd. ("Company") will be held on Thursday, October 30, 2014, at 9:30 am (Israel Time), at the offices of the Comp
Read more →ENLVBio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal
Bio Blast Pharma Announces Initiation of its Canadian OPMD Clinical Study Center at McGill University, Montreal TEL AVIV, Israel, September 22, 2014 - Bio Blast Pharma Ltd (NasdaqGM: ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful th
Read more →ENLVBioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3 HOPEMD Study in OPMD Interim Data on First 11 Patients in the Ongoing
BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results with Cabaletta, Interim Safety Results from Phase 2/3 HOPEMD Study in OPMD TEL AVIV, Israel, September 17, 2014 - BioBlast Pharma Ltd (NasdaqGM: ORPN), a clinical-stage biotechnology company committed t
Read more →Competitive Position
How ENLV ranks across every disease it competes inCompetitive Position is a premium feature
See how ENLV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial